GWASdb v2: an update database for human genetic variants identified by genome-wide association studies.

GWASdb v2: an update database for human genetic variants identified by genome-wide association studies.
复制标题

GWASdb v2:通过全基因组关联研究确定的人类遗传变异的更新数据库。

DOI:
10.1093/nar/gkv1317
复制
发表时间:
2016-01-04
影响因子:
14.9
通讯作者:
Wang J
Wang J
中科院分区:
生物学2区
文献类型:
--
作者:
Li MJ;Liu Z;Wang P;Wong MP;Nelson MR;Kocher JP;Yeager M;Sham PC;Chanock SJ;Xia Z;Wang J

文献摘要

被引文献

相似文献

全基因组关联研究 (GWAS) 目前已成为研究单核苷酸多态性 (SNP) 与性状关联的常规方法,已发现了超过一万个重要的性状/疾病相关 SNP (TAS)。在这里,我们更新了 GWASdb(GWASdb v2,http://jjwanglab.org/gwasdb),它为 GWAS TAS 提供全面的数据管理和知识集成。这些更新包括: (i) 截至 2015 年 8 月,我们从 PubMed 和其他资源收集了 2479 篇独特的出版物; (ii) 我们进一步从每份原始出版物中筛选出中等程度的 SNP 性状关联(P 值 < 1.0×10−3),并在所有 GWASdb v2 收集的研究中总共生成了 252 530 个独特的 TAS; (iii) 我们手动将 1610 个 GWAS 性状映射到 501 个人类表型本体 (HPO) 术语、435 个疾病本体 (DO) 术语和 228 个疾病本体精简版 (DOLite) 术语。对于每个本体术语,我们还预测了假定的因果基因; (iv) 我们为每项研究策划了详细的亚人群和相关样本量; (v) 重要的是,我们通过整合基于基因的信息、ENCODE ChIP-seq 分析、eQTL、群体单倍型、跨多个生物领域的功能预测、进化信号和疾病相关注释,对每个 TAS 进行了广泛的功能注释; (vi) 此外,我们在本次更新中编制了涉及 257 种药物的 650 项药物遗传学研究的 SNP-药物反应关联数据集; (七)最后,我们改进了网站的用户界面。
Genome-wide association studies (GWASs), now as a routine approach to study single-nucleotide polymorphism (SNP)-trait association, have uncovered over ten thousand significant trait/disease associated SNPs (TASs). Here, we updated GWASdb (GWASdb v2, http://jjwanglab.org/gwasdb) which provides comprehensive data curation and knowledge integration for GWAS TASs. These updates include: (i) Up to August 2015, we collected 2479 unique publications from PubMed and other resources; (ii) We further curated moderate SNP-trait associations (P-value < 1.0×10−3) from each original publication, and generated a total of 252 530 unique TASs in all GWASdb v2 collected studies; (iii) We manually mapped 1610 GWAS traits to 501 Human Phenotype Ontology (HPO) terms, 435 Disease Ontology (DO) terms and 228 Disease Ontology Lite (DOLite) terms. For each ontology term, we also predicted the putative causal genes; (iv) We curated the detailed sub-populations and related sample size for each study; (v) Importantly, we performed extensive function annotation for each TAS by incorporating gene-based information, ENCODE ChIP-seq assays, eQTL, population haplotype, functional prediction across multiple biological domains, evolutionary signals and disease-related annotation; (vi) Additionally, we compiled a SNP-drug response association dataset for 650 pharmacogenetic studies involving 257 drugs in this update; (vii) Last, we improved the user interface of website.